CinnaFact®

Description

Buserelin acetate is a synthetic peptide analog of the natural gonadotropin releasing hormone (GnRH/LHRH) with enhanced biological activity. CinnaFact^® is the brand name for buserelin acetate produced by CinnaGen Co. Each vial of CinnaFact^® contains 5.5 mg of injection solution (1 mg/mL; 5.5 ml)

Indications

• CinnaFact^® (Buserelin acetate) is indicated for advanced prostate cancer and endometriosis. CinnaFact® is also used for pituitary down-regulation during assisted reproductive technology (ART) procedures.

Important safety information

• CinnaFact ^® is contraindicated in pregnancy, breast-feeding, and patients with:

Hypersensitivity to buserelin or any component of the formulation and women with undiagnosed abnormal vaginal bleeding.

• Anemia: Testosterone suppression is associated with the development of anemia.
• CNS effects: May cause dizziness, which may impair physical or mental abilities.
• Decreased bone density: Prolonged use of a luteinizing hormone releasing hormone (LHRH) agonist may cause decreased bone mineral density and possibly lead to osteoporosis and increased risk of skeletal bone fracture.
• Disease fare: A transient exacerbation of the signs and symptoms of the disease process may be observed with the initiation of therapy in prostate cancer and endometriosis patients.
•  Hypogonadism: Hypogonadism is an anticipated effect of androgen deprivation therapy.
• Pituitary adenoma: The development of pituitary adenomas may rarely be seen with long-term therapy.
• Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease.
• Diabetes: Reduced glucose tolerance and loss of blood glucose control have been noted in rare cases.